Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Gentian Diagnostics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Gentian Diagnostics's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Gentian Diagnostics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Gentian Diagnostics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Gentian Diagnostics's earnings growth to the Norway market average as no estimate data is available.
Unable to compare Gentian Diagnostics's revenue growth to the Norway market average as no estimate data is available.
Unable to determine if Gentian Diagnostics is high growth as no earnings estimate data is available.
Unable to determine if Gentian Diagnostics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Gentian Diagnostics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Gentian Diagnostics's finances.
The net worth of a company is the difference between its assets and liabilities.
Gentian Diagnostics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Gentian Diagnostics's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Gentian Diagnostics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is covered by short term assets, assets are 187.5x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Hilja Ibert has been the Chief Executive Officer of Gentian Diagnostics AS since July 16, 2018. Dr. Ibert has more than 25 years' experience from the international diagnostic industry, and an extensive and strong leadership experience. Dr. Ibert has previously held the position as Vice President International Diagnostic Solutions at Hologic, as well as several senior positions within Becton Dickinson and bioMerieux within the field of diagnostics. Dr. Ibert holds a PhD degree in Nutrition Science from the University of Bonn, Germany. Dr. Ibert also has experience with early stage R&D companies, lastly in her position as Chief Executive Officer for miDiagnostics in Belgium.
Insufficient data for Hilja to compare compensation growth.
Insufficient data for Hilja to establish whether their remuneration is reasonable compared to companies of similar size in Norway.
Chief Executive Officer
Chief Financial Officer
Vice President of Research and Development
Board of Directors
Who owns this company?
Recent Insider Trading
More shares have been bought than sold by Gentian Diagnostics individual insiders in the past 3 months.
Gentian Diagnostics AS researches, develops, and produces biochemical reagents for use in medical diagnostics and research. It offers in-vitro diagnostic (IVD) and molecular diagnostic tests for medical laboratories and universities worldwide. The company’s products include Calprotectin, a particle enhanced turbidimetric immunoassay (PETIA) for quantitative analysis of total calprotectin in plasma; and Canine CRP, an IVD test for the quantitative determination of Canine CRP in dog serum plasma. It also offers NGAL, a PETIA for IVD testing of neutrophil gelatinase-associated lipocalin in human urine and plasma samples; Cystatin C, a PETIA for use on a range of clinical chemistry analyzers; PreTect HPV-Proofer, an assay for the qualitative detection of the presence of human papillomavirus; and PreTect SEE, a control test for NILM cytology. The company was founded in 2001 and is headquartered in Moss, Norway.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.